Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

delta9-tetrahydrocannabinol/cannabidiol combination agent

A sub-micron spray containing a nanoparticle water soluble equimolar solution composed of delta-9-tetrahydrocannabinol (delta-9-THC; d9-THC), an analogue of tetrahydrocannabinol (THC) and the primary form of THC found in the Cannabis sativa L. plant, and cannabidiol (CBD), a phytocannabinoid derived from Cannabis species, with potential analgesic activity. Upon administration to the oro-buccal membrane, d9-THC/CBD combination agent binds to and activates the cannabinoid G-protein coupled receptor (CBR) located in the central nervous system (CNS). This activates the inwardly rectifying potassium channels, which decrease presynaptic neuron firing, and inhibits voltage-sensitive calcium channels that decrease neurotransmitter release. This inhibits excitatory postsynaptic neuronal transmission, and inhibits the release of pro-inflammatory mediators. This provides an analgesic effect.
Synonym:d9-THC/CBD nanoparticle-based combination agent
US brand name:NanaBis
Code name:MDCNB-01
Search NCI's Drug Dictionary